Repligen Corporation reported $785M of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $785M (to Q2 2026). Net income: $42M, trailing twelve months to Q2 2026. Free cash flow: $112M, trailing twelve months to Q2 2026. Operating margin: 8.2%, trailing twelve months to Q2 2026.

RGENRepligen Corporation

Healthcare

$173.84+42% 1Y

$173.84

$102.8752 weeks$194.62

RGEN as reported

Repligen Corporation reported $785M of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed.

$785M

Revenue, trailing twelve months · to Q2 2026 · +16% against the twelve months before

Net income: $42M
Net income · −400% year on year · trailing twelve months to Q2 2026
Free cash flow: $112M
Free cash flow · +2.8% year on year · trailing twelve months to Q2 2026
Operating margin: 8.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RGEN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$785M	+16%	Q2 2026
Net income	$42M	−400%	Q2 2026
EPS	$0.73	−381%	Q2 2026
Gross margin	54%	n/a	Q2 2026
Operating margin	8.2%	n/a	Q2 2026
Net margin	5.3%	n/a	Q2 2026
ROE	1.7%	n/a	Q2 2026
ROA	1.2%	n/a	Q2 2026
ROIC	2.0%	n/a	Q2 2026
Free cash flow	$112M	+2.8%	Q2 2026
P/E	238	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.